Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6-8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5-55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD. It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy. To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jcem.83.2.4538DOI Listing

Publication Analysis

Top Keywords

days 131i
12
131i therapy
12
cure rate
12
therapeutic efficacy
8
5-55 days
8
received atd
8
ptu discontinued
8
ptu mmi
8
131i
6
ptu
6

Similar Publications

Objectives: To investigate the effects of selenium on functional and histopathological changes and mRNA expression levels of insulin-like growth factors 1 and 2 (IGF-1 and -2) and aquaporins 4 and 5 (AQP-4 and -5) in 131I-induced damaged rat parotid glands.

Methods: Rats were divided into three groups: iodotherapy-with-selenium, iodotherapy-only, and control. Rats in the iodotherapy-with-selenium group were intragastrically administered 131I on the first day and selenomethionine through drinking water.

View Article and Find Full Text PDF

Assessment of surface contamination of low-dose radioactive iodine (131I) treatment container.

Nucl Med Commun

December 2024

Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Pocheon-si.

With the advancement of radiotherapy technology in the medical field, the amount of radioactive waste has rapidly increased, and the International Atomic Energy Agency (IAEA) has proposed waste deregulation standards based on individual dose, collective dose, and nuclide concentration. The purpose of this study is to define the standard period (1 day) required to measure collected radioactive waste using direct and indirect methods with a radioactivity meter, ensure that the radiation dose remains below the allowable level, and transport the waste safely. In this study, 131I low-dose (30 mCi) radioactive waste discarded after radioiodine treatment at a medical institution was collected, and a measuring container was prepared to measure radioactivity concentration according to IAEA standards.

View Article and Find Full Text PDF

Disease management of malignant struma ovarii.

Hell J Nucl Med

December 2024

Department of Nuclear Medicine, Qiantang Branch of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Article Synopsis
  • - Malignant struma ovarii (MSO) is a rare type of ovarian goiter that meets criteria for malignant thyroid tumors and can show invasive spread, with serum thyroglobulin (Tg) levels helping to differentiate it from other ovarian cancers.
  • - A case study is presented involving a 54-year-old woman with abdominal pain, diagnosed post-surgery with highly differentiated follicular thyroid carcinoma originating from both ovaries, which had spread to other areas.
  • - After undergoing total thyroidectomy and iodine-131 treatment, her follow-up after one year showed no significant abnormalities, highlighting the need for further discussion on clinical management and monitoring of Tg levels in MSO cases.
View Article and Find Full Text PDF

Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report.

Gland Surg

October 2024

Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health, Biosciences, The University of Tokushima, Tokushima, Japan.

Background: Although lenvatinib is effective for unresectable thyroid carcinoma, it may cause adverse events owing to rapid tumor shrinkage or necrosis. Pneumothorax during lenvatinib therapy is rare. However, once it occurs, it can become a refractory and fatal complication.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!